Clinical Trial Update: A Study to Evaluate Corrected QT Interval From Clinical Studies Conducted With Bevacizumab

View source ↗

Summary

This update notes that a study evaluating the corrected QT interval with bevacizumab has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Carcinoma | Status: WITHDRAWN